|
|
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
|
|
ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.
A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
Overviews
|
|
|
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Revlimid
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Michel Attal, MD
Hôpital Purpan
Toulouse, France |
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
Philip McCarthy, MD
Roswell Park Cancer Institute
Buffalo, New York, USA |
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
Thalomid
|
|
|
Frits Van Rhee, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
Velcade
|
|
|
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California, USA |
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Frits Van Rhee, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
Douglas Joshua, MD
University of Sydney
Sydney, Australia |
|
New Agents
|
|
|
Donald Benson, MD
The Ohio State Comprehensive Cancer Center
Columbus, Ohio, USA |
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA |
|
|
|
|
Saad Usmani, MD
University of Connecticut Health Center
Farmington, Connecticut, USA |
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA |
|
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Transplant
|
|
|
|
Michel Attal, MD
Hôpital Purpan
Toulouse, France |
|
|
|
|
David Seldin, MD
Boston University School of Medicine
Boston, Massachusetts, USA |
|
|
|
|
Muthu Veeraputhiran, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
|
Philip McCarthy, MD
Roswell Park Cancer Institute
Buffalo, New York, USA |
|
Relapsed/Refractory
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA |
|
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Others
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Christoph Heuck, MD
Montefiore Medical Center
Bronx, New York, USA |
|
|
|
|
Gareth Morgan, MD
The Royal Marsden Hospital
London, England |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
back
print
related articles
Be the first to comment